Apparent mineralocorticoid excess

Journal of Steroid Biochemistry and Molecular Biology

Volumn 165, Issue , 2017, Pages 151-153

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

11 hydroxysteroid dehydrogenase type 2; Aldosterone; Cortisol; Mineralocorticoid receptors; Urinary steroid metabolites

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE SYNTHASE; AMILORIDE; CALCIUM CHANNEL BLOCKING AGENT; CORTISONE; DEHYDROCORTICOSTERONE; EPLERENONE; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HYDROCORTISONE; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; POTASSIUM; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT; STEROID;

ALDOSTERONE BLOOD LEVEL; APPARENT MINERALOCORTICOID EXCESS SYNDROME; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME ACTIVITY; GLYCYRRHIZA; HEART FAILURE; HIGH POTASSIUM INTAKE; HORMONE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERTENSION; HYPOKALEMIA; NONHUMAN; PATHOGENESIS; REVIEW; SMOKELESS TOBACCO; SODIUM RESTRICTION; BLOOD; CHEMISTRY; COMPLICATION; DIET; GENETICS; METABOLISM; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; URINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; CORTISONE; DIAGNOSIS, DIFFERENTIAL; DIET; HUMANS; HYDROCORTISONE; HYPERTENSION; HYPOKALEMIA; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; MINERALOCORTICOIDS; RECEPTORS, MINERALOCORTICOID; STEROIDS;

EID: 84960517575     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.03.010     Document Type: Review

References (19)

1. [1] Ulick, S., Levine, L.S., Gunczier, P., Zanconato, G., Ramirez, L.C., Rauh, W., Rösler, A., Bradlow, H.L., New, M.I., A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J. Clin. Endocrinol. Metab. 49 (1979), 19–22.
2. [2] Oberfield, S.E., Levine, L.S., Carey, R.M., Greig, F., Ulilck, S., New, M.I., Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 56 (1983), 332–339.
3. [3] Harinck, H.I., van Brummelen, P., Van Seters, A.P., Moolenaar, A.J., Apparent mineralocorticoid excess and deficient 11 beta-oxidation of cortisol in a young female. Clin. Endocrinol. 21 (1984), 505–514.
4. [4] Monder, C., Shackleton, C.H., Bradlow, H.L., New, M.I., Stoner, E., Iohan, F., Lakshmi, V., The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism. J. Clin. Endocrinol. Metab. 63 (1986), 550–557.
5. [5] Stewart, P.M., Corrie, J.E.T., Shackleton, C.H.L., Edwards, C.R.W., Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J. Clin. Invest. 82 (1988), 340–349.
6. [6] Agarwal, A.K., Monder, C., Eckstein, B., White, P.C., Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J. Biol. Chem. 264 (1989), 18939–18943.
7. [7] Rusvai, E., Naray-Fejes-Toth, A., A new isoform of 11 b-hydroxysteroid dehydrogenase in aldosterone target cells. J. Biol. Chem. 268 (1993), 10717–10720.
8. [8] Albiston, A.L., Smith, R.E., Obeyesekere, V.R., Krozowski, Z.S., Cloning of the 11 beta type II enzyme from human kidney. Endocr. Res. 21 (1995), 399–409.
9. [9] Wilson, R.C., Krozowski, Z.S., Li, K., Obeyesekere, V.R., Razzaghy-Azar, M., Harbison, M.D., Wei, J.Q., Shackleton, C.H., Funder, J.W., New, M.I., A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80 (1995), 2263–2266.
10. [10] Obeyesekere, V.R., Ferrari, P., Andrews, R.K., Wilson, R.C., New, M.I., Funder, J.W., Krozowski, Z.S., The R337C mutation generates a high Km 11 beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80 (1995), 3381–3383.
11. [11] Funder, J.W., Myles, K., Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137 (2013), 5264–5268.
12. [12] Fjeld, C., Birdsong, W., Goodman, R., Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 9202–9207.
13. [13] Funder, J.W., RALES, EPHESUS and redox. J. Steroid Biochem. Mol. Biol. 93 (2005), 121–125.
14. [14] Kassahn, K.S., Ragan, M.A., Funder, J.W., Mineralocorticoid receptors: evolutionary and pathophysiological considerations. Endocrinology 152 (2011), 1883–1890.
15. [15] Shibata, S., Rinehart, J., Zhang, J., Moeckel, G., Castaneda-Bueno, M., Stiegler, A.L., Boggon, T.J., Gamba, G., Lifton, R.P., Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab. 18 (2013), 660–671.
16. [16] Funder, J.W., Angiotensin retains sodium by dephosphorylating mineralocorticoid receptors in renal intercalated cells. Cell Metab. 18 (2013), 609–610.
17. [17] Funder, J.W., Adam, W.R., Mantero, F., Kraft, N., Ulick, S., The aetiology of a syndrome of factitious mineralocorticoid excess: a steroid-containing nasal spray. J. Clin. Endocrinol. Metab. 49 (1979), 842–846.
18. [18] Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J., Wittes, J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341 (1999), 709–717.
19. [19] Mihailidou, A.S., Loan Le, T.Y., Mardini, M., Funder, J.W., Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54 (2009), 1306–1312.